

epinephrine, histamine, 5-hydroxytryptamine (serotonin) and others. It was shown that ketamine produced a decrease of the concentration of serotonin in the brain of rats²². This possible decrease of serotonin could result the decrease in the stimulation of cAMP formation reported in our experiments. It is necessary to notice that there is conformity between the maximal depressive effect of keta-

mine on the thalamus system, described in the literature, and the maximal decrease of cAMP concentration in the same region reported in our study.

Further studies will be required to elucidate these possibilities, especially in relation to the kinetics of accumulation and elimination of ketamine in various areas of the rat brain.

- 1 Conducted under contract No 10.4.2 with the Polish Academy of Science.
- 2 G. C. Palmer, F. Sulser and G. A. Robison, *Neuropharmacology* 12, 327 (1973).
- 3 P. Uzunow and B. Weiss, *Adv. cycl. Nucleot. Res.* 1, 435 (1972).
- 4 H. Iizuka, K. Adachi, K. M. Halprin and V. Levine, *Biochim. biophys. Acta* 444, 685 (1976).
- 5 G. C. Palmer, G. A. Robison and F. Sulser, *Biochem. Pharmac.* 20, 236 (1971).
- 6 G. M. Picen and H. Jarrott, *Biochem. Pharmac.* 24, 2255 (1975).
- 7 B. Weiss and S. J. Strada, *Adv. cycl. Nucleot. Res.* 1, 357 (1972).
- 8 D. Tsang and S. Lal, *Can. J. Physiol. Pharmac.* 55, 1263 (1977).
- 9 K. Dismukes and J. W. Daly, *Life Sci.* 17, 199 (1975).
- 10 D. J. Deery, *Gen. comp. Endocr.* 25, 395 (1975).
- 11 A. Gilman, *Proc. natl Acad. Sci.* 67, 305 (1970).
- 12 B. L. Brown, J. D. M. Albano, R. P. Ekins and A. M. Sgherzi, *Biochem. J.* 121, 561 (1971).
- 13 R. W. Butcher, R. J. Ho, H. C. Heng and E. W. Sutherland, *J. biol. Chem.* 240, 4515 (1965).
- 14 O. H. Lowry, N. J. Rosenbrough, A. L. Farr and R. J. Randall, *J. biol. Chem.* 193, 265 (1951).
- 15 Parke Davis Co., Ketalar, a unique anaesthetic, No. 3639, Feb. 1972.
- 16 N. A. Lassen and M. S. Christensen, *Br. J. Anaesth.* 48, 719 (1976).
- 17 D. Langrehr, *Anaesthesist* 16, 308 (1967).
- 18 R. Bazangour, *Anesth. Analg. Réanim.* 32, 367 (1975).
- 19 D. L. Sparks, *Anesth. Analg.* 54, 189 (1975).
- 20 I. Yusuke and K. Ichyanagi, *Anaesthesia* 29, 222 (1974).
- 21 M. S. Schwarz, *Anaesthesia* 29, 135 (1974).
- 22 M. Szymańska-Kowalska, *J. Pol.* 7, (1976).

Glutamine synthetase activity in subdivisions of brain of the shark, *Squalus acanthias*¹

J. T. Webb and G. W. Brown, Jr


Laboratory of Biochemical Ecology, College of Fisheries, University of Washington, Seattle (Washington 98195, USA), 6 November 1979

Summary. Specific activity of glutamine synthetase in *Squalus acanthias* (spiny dogfish) central nervous system regions was highest in the cerebellum and lowest in the spinal cord. The levels of activity may relate to the excitability of each region by regulating the glutamate pool.

The only known physiologically significant route of glutamine synthesis in all species is the activity of L-glutamate:ammonia ligase (ADP-forming) (EC 6.3.1.2)². Presence of this enzyme in brain tissue has been known for some time^{3,4}. Waelsch⁵ suggested that glutamine synthetase regulates the glutamate pool in the brain. The proposed function of glutamate as an excitatory transmitter has been reviewed previously^{6,7}. An ammonia detoxification role has also been considered for mammals⁸ and for fish^{9,10}. The recent finding that the vast majority of glutamine synthetase activity in rat brain is restricted to glial cells⁸ may help to clarify the role of glutamine synthetase in the brain. As part of a comparative study of glutamine synthetase in fish tissues^{11,12}, regions of *Squalus acanthias* (spiny dogfish) brain were examined to determine whether activity was localized in a specific area of the central nervous system.

Brain tissue was excised from freshly sacrificed, female *Squalus acanthias* (length: 87–105 cm). Subdivision and identification of brain regions was according to Gilbert¹³ and Smith¹⁴. The γ -glutamyl hydroxamate standard, L-glutamine, NaADP, imidazole, KH_2AsO_4 , and bovine serum albumin were obtained from Sigma Chemical Co., St. Louis, Mo. Hydroxylamine-HCl was obtained from Merck and Co., Rahway, N.J.

The freshly excised brain segments were homogenized with 9 volumes of water in glass, hand homogenizers at 0–5 °C and assayed within 30 min. The assay for glutamine synthetase activity followed the depicted reaction as described by Webb and Brown¹¹.



Glutamine synthetase activities and protein content: regions of *Squalus acanthias* brain and spinal cord

| | Tissue activity | Protein content | Specific activity |
|-----------------------------|-----------------|-----------------|-------------------|
| Cerebellum | 22.4 ± 2.2 (3) | 69 ± 7 (3) | 0.33 ± 0.03 (3) |
| Cerebrum (Telencephalon) | 16.4 ± 2.9 (3) | 61 ± 10 (3) | 0.27 ± 0.00 (3) |
| Medulla oblongata | 17.9 ± 1.8 (3) | 75 ± 5 (3) | 0.24 ± 0.02 (3) |
| Optic lobe | 15.5 ± 2.3 (3) | 74 ± 12 (3) | 0.21 ± 0.00 (3) |
| Spinal cord | 9.3 ± 0.8 (3) | 75 ± 4 (3) | 0.12 ± 0.01 (3) |

The means ± SD are shown with number of samples in parentheses. Tissue activity is expressed as units of glutamine synthetase activity per g tissue. Protein is expressed as mg per g tissue. Specific activity is expressed as units of glutamine synthetase activity per mg protein.

Concentrations of substrates in the assay mixture were: 60 mM L-glutamine, 15 mM hydroxylamine (NH₂OH), 0.4 mM Na₂ADP, 3 mM MnCl₂, 20 mM KH₂AsO₄, and 40 mM imidazole. Incubations were maintained at 25 °C and pH 6.7. Activity was measured by formation of a relatively stable (5–30 min) complex of FeCl₃ and γ -glutamyl hydroxamate in acid solution¹⁵ compared with a γ -glutamyl hydroxamate standard at 500 nm. A unit of glutamine synthetase activity is defined as 1 μ mole γ -glutamyl hydroxamate produced per min at 25 °C. Protein was determined by the biuret method of Zamenhof¹⁶ with bovine serum albumin as a standard.

The specific activity of each *Squalus acanthias* brain region shows little variation as shown by the standard deviations

in column 4 of the table. As observed by others^{17–19}, brain regions have different, but not a highly regionalized, specific activity of glutamine synthetase. The region of highest activity differs among these reports and may relate to the relative need of the brain regions to detoxify ammonia^{8,19}. The relationship of glutamine synthetase to glial content^{8,19} of each brain region could also reflect the relative glial content of these regions. As discussed by Martinez-Hernandez et al.⁸, this could indicate control by glutamine synthetase of the glutamate pool and regulation of brain excitability. If this is the case, the different excitability of brain regions as expressed by glutamine synthetase activity in *Squalus acanthias* and other animals may be associated with the prominence of each region's function relative to each species' central nervous system adaptations.

- 1 Publication No. 14 from the Laboratory of Biochemical Ecology. Contribution No. 527, College of Fisheries, University of Washington. This work was supported in part by a fellowship from the national Wildlife Federation and a Pacific Fisheries Biologists' scholarship to J.T.W.
- 2 M. Florkin and E.H. Stotz, Ed. Comprehensive Biochemistry, vol. 13, 3rd edn. Elsevier Scientific, Amsterdam 1973.
- 3 H. Waelsch, P. Owades, E. Borek, N. Grossowicz and M. Schou, Archs Biochem. 17, 237 (1950).
- 4 H. Weil-Malherbe, Physiol. Rev. 30, 549 (1950).
- 5 H. Waelsch, Adv. Protein Chem. 6, 299 (1951).
- 6 J.R. Cooper, F.E. Bloom and R.H. Roth, The Biochemical Basis of Neuropharmacology, p. 164. Oxford University Press, New York 1970.
- 7 N. Davidson, Neurotransmitter Amino Acids. Academic Press, New York 1976.
- 8 A. Martinez-Hernandez, K.P. Bell and M.D. Norenberg, Science 195, 1356 (1977).
- 9 C. Wu, Comp. Biochem. Physiol. 8, 335 (1963).
- 10 P.M. Mehrle and R.A. Bloomfield, Toxic. appl. Pharmac. 27, 355 (1974).
- 11 J.T. Webb and G.W. Brown, Jr, Comp. Biochem. Physiol. 54B, 171 (1976).
- 12 J.T. Webb, Dissertation, University of Washington, Seattle 1979.
- 13 S.G. Gilbert, Pictorial Anatomy of the Dogfish, p. 38. University of Washington Press, Seattle 1973.
- 14 L.S. Smith, Introductory Anatomy and Biology of Selected Fish and Shellfish. College of Fisheries, University of Washington, Seattle 1973.
- 15 F. Lipmann and L.C. Tuttle, J. biol. Chem. 159, 21 (1945).
- 16 S. Zamenhof, in: Methods in Enzymology p. 702. Ed. S.P. Colowick and N.O. Kaplan. Academic Press, New York 1957.
- 17 D. Rudnick and H. Waelsch, J. exp. Zool. 129, 309 (1955).
- 18 S. Berl, Biochemistry 5, 916 (1966).
- 19 H. Kluge, W. Hartmann and V. Wiczorek, Brain Res. 32, 266 (1971).

Conversion of mammalian cyclic GMP-dependent protein kinase into modulator-dependent protein kinase (type II) in vitro

W. N. Kuo¹, L. P. Liu, C. F. Duggans, K. M. Foggie, M. J. McNeal and K. Perry

Division of Science and Mathematics, Bethune-Cookman College, Daytona Beach (Florida 32015, USA), 25 October 1979

Summary. The spontaneous conversion of mammalian cyclic GMP-dependent protein kinase (G-PK) into modulator-dependent protein kinase (type II) (M-PK_{II}) in the absence of cGMP or histone was observed in vitro. The findings, together with similarity in substrate protein specificity, suggest that M-PK_{II} is the catalytic subunit of mammalian G-PK.

Following the initial discovery of G-PK in arthropod tissues^{2,3}, the cGMP target enzyme was subsequently found in some mammalian tissues⁴. Recently, substantial progress concerning mammalian G-PK has been made, for example: the discovery that crude protein kinase modulator (PKM)^{5–8} or purified stimulatory protein kinase modulator (PKM_s)^{7,8} is required for maximal G-PK activity under the incubation condition of lower Mg⁺⁺ concentration; the dissociation of G-PK holoenzyme into its catalytic subunit in the presence of exceedingly high concentration of cGMP or histone^{9,10}; and the stimulation of its catalytic subunit in the presence of stimulatory modulator alone¹⁰. In spite of the above progress, some tasks yet remain. Among them are the conversion of G-PK holoenzyme into its subunits and the reversal of the process in vitro under low concentrations of histone, cGMP, or Mg⁺⁺; and the stabilization of the subunits in vitro. We now report on the spontaneous con-

version of G-PK into M-PK_{II} in vitro in the absence of cGMP or histone.

Materials and methods. [γ -³²P] ATP was purchased from New England Nuclear. cGMP and cAMP were obtained from Boehringer Mannheim (FRG); arginine-rich histone (HA) was obtained from Worthington; another histone (type II-S) and protamine chloride (grade V) were obtained from Sigma. Sephadex G-100 and G-200 were from Pharmacia.

Crude PKM was prepared from liver extracts of 8-month-old ICR mice by boiling and trichloroacetic acid-precipitation^{5–8}. PKM_s and inhibitory modulator (PKM_i) were partially purified by Sephadex G-100 gel filtration^{7,8}. G-PK from guinea-pig fetal lung was purified by Sephadex G-200¹², and the active fractions were pooled, concentrated to about 5 ml (Amicon concentrator using UM-10 membrane). This concentrated G-PK was stored at –20 °C for 8 months